Loading...
A new monoclonal antibody that blocks dimerisation and inhibits c-kit mutation-driven tumour growth
PURPOSE: Imatinib, a small-molecule tyrosine kinase inhibitor, has shown good clinical activity by inhibiting adenosine triphosphate (ATP) binding to the receptor. Unfortunately, majority of patients eventually develop drug resistance, which limits the long-term benefits of the tyrosine kinase inhib...
Na minha lista:
| Udgivet i: | J Cancer Res Clin Oncol |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Springer Berlin Heidelberg
2021
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7954730/ https://ncbi.nlm.nih.gov/pubmed/33389076 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00432-020-03490-6 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|